Skip to content
DeepViews
[XASE]

Regentis Biomaterials Ltd. (RGNT)

$2.00

更新 — ET · 市场数据 POLYGON · 财务数据 SEC EDGAR

市值
$14.47M
企业价值
$8.74M
市盈率
-1.1
股息率
0.00%
EV/EBITDA
N/A
公司简介
关于
关于 Regentis Biomaterials Ltd.

Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing tissue repair solutions that restore health and enhance the quality of life of patients. It is focused on orthopedic treatments using its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue (inflamed cartilage and bone tissue). Gelrin is a hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen (a biologically inactivated protein that normally has a role in blood clotting). Its product is GelrinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage.

员工人数

8

Exchange

XASE

官网
Source: Polygon.io
评分
竞争壁垒
竞争壁垒

需要至少 3 年年度财务数据来评估竞争壁垒。

市场信号
估值
盈利
内部人交易
内部人备案活动

首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。

加载 SEC 内部人备案数据...
超级投资者
财务健康
财务健康

资本结构

总权益$39.84M
总债务$1.65M
债务权益比0.04
现金及等价物$7.38M

现金流

经营现金流$-1.38M
自由现金流$0.00M
自由现金流率N/A
P/FCF 比率N/A
Source: Polygon.io · SEC EDGAR
股息
最新资讯
Recent News

免责声明:本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。